STRATEGIC PARTNERSHIPS AND ONGOING CLINICAL TRIALS

---

The human clinical study will be conducted at the prestigious Friedman Diabetes Institute at Lenox Hill Hospital in New York City, ensuring access to a diverse patient population and robust data collection. 

The Friedman Diabetes Institute is ranked #9 out of 5,000 medical centers nationwide in Adult Diabetes and Endocrinology by the U.S. News & World Report.

This clinical study aims to evaluate the accuracy of a novel, noninvasive prototype device for measuring blood glucose levels. This technology has the potential to revolutionize diabetes management by offering a painless, convenient, and cost-effective alternative to traditional finger-prick methods. 

Participants' blood glucose levels will be measured simultaneously using the noninvasive device and the standard finger-prick method, allowing for a rigorous head-to-head comparison and establishing the device's accuracy. Positive results from this study could pave the way for regulatory approval and commercialization, opening up a massive market opportunity in the rapidly growing diabetes management sector.

Dimiter Avtanski, PhD  - TEAM LEAD, Glycosa Clinical Trial

Director, Endocrine Research Laboratory 

Friedman Diabetes Institute at Lenox Hill Hospital, New York

Associate Professor of Medicine 

Zucker School of Medicine at Hofstra/Northwell, Hempstead

Assistant Professor 

The Feinstein Institutes for Medical Research, Manhasset